GlassScriptPhysician profile
Adeel Rahman
NPI 1225052442
$1,968.05
in general payments reported to CMS, 2019-2025
34 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $155 · 2021: $176 · 2022: $198 · 2023: $227 · 2024: $462 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.57 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $252.59 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Abbvie INC. | $130.68 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $125.87 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $122.95 | 2023-2025 | Ajovy, Austedo Xr |
| Ucb, INC. | $121.22 | 2024-2025 | Nayzilam, Briviact |
| Amgen INC. | $110.30 | 2019-2025 | Uplizna, Repatha |
| Astrazeneca Pharmaceuticals LP | $93.84 | 2020-2025 | Lokelma |
| Pfizer INC. | $85.01 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $84.81 | 2023-2024 | Rexulti |
| Biogen, INC. | $64.33 | 2021-2025 | Leqembi |
| Acorda Therapeutics, INC | $60.52 | 2022-2024 | Inbrija |
| Hyperfine Operations, INC. | $59.63 | 2025 | Swoop |
| Alexion Pharmaceuticals, INC. | $55.76 | 2024-2025 | Ultomiris |
| Novo Nordisk INC | $48.64 | 2022 | |
| Vanda Pharmaceuticals INC. | $43.70 | 2024-2025 | Ponvory |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $42.25 | 2020-2022 | |
| Abbott Laboratories | $40.72 | 2023-2025 | Infinity |
| W. L. Gore & Associates, INC. | $38.52 | 2021 | |
| Amneal Pharmaceuticals LLC | $35.78 | 2019-2024 | Ongentys 50mg Capsules 30 |
| Janssen Biotech, INC. | $35.00 | 2025 | Simponi Aria, Tremfya |
| Lundbeck LLC | $31.34 | 2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $31.31 | 2022 | |
| Sk Life Science, INC. | $27.97 | 2024 | |
| Springworks Therapeutics, INC. | $27.58 | 2025 | Gomekli |
| Genzyme Corporation | $24.96 | 2022 | |
| Acadia Pharmaceuticals INC | $23.21 | 2019 | |
| Adamas Pharmaceuticals, INC. | $22.95 | 2020 | |
| Merz Pharmaceuticals, LLC | $21.98 | 2025 | Inbrija |
| Neurelis, INC. | $21.72 | 2023 | Valtoco |
| Neurocrine Biosciences, INC. | $21.10 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.28 | 2021 | |
| Harmony Biosciences LLC | $18.74 | 2024 | |
| Allergan, INC. | $11.99 | 2020 | |
| Supernus Pharmaceuticals, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeel Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.